Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting

This is a video synopsis/summary of an OncLive Insights^® discussion involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

This segment focuses on deciding between monotherapy versus dual immunotherapy approaches in melanoma. Dr Khushalani states that based on the negative data from the CheckMate 915 trial, there is currently no role for adjuvant doublet immunotherapy with anti–PD-1 plus anti–CTLA-4 inhibition for patients with resected stage III disease. The one exception is patients with resected stage IV disease, who have very high recurrence risk even after surgery. Data from an IMMUNED in these patients showed improved relapse-free and overall survival with the adjuvant ipilimumab/nivolumab combination versus nivolumab alone or observation. Thus, Dr Khushalani will discuss adjuvant ipilimumab and nivolumab as an option for patients with resected stage IV disease, considering modified dosing to mitigate toxicity risks. The efficacy of neoadjuvant nivolumab plus relatlimab (LAG-3 pathway inhibitor) is still unknown pending trial results.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.